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Abstract
With the advent of widespread genomic testing for diagnostic indications and disease risk assessment, there is increased need to
optimize genetic counseling services to support the scalable delivery of precision medicine. Here, we describe how we opera-
tionalized the reciprocal engagement model of genetic counseling practice to develop a framework of counseling components
and strategies for the delivery of genomic results. This framework was constructed based upon qualitative research with patients
receiving genomic counseling following online receipt of potentially actionable complex disease and pharmacogenomics reports.
Consultation with a transdisciplinary group of investigators, including practicing genetic counselors, was sought to ensure broad
scope and applicability of these strategies for use with any large-scale genomic testing effort. We preserve the provision of pre-
test education and informed consent as established in Mendelian/single-gene disease genetic counseling practice. Following
receipt of genomic results, patients are afforded the opportunity to tailor the counseling agenda by selecting the specific test
results they wish to discuss, specifying questions for discussion, and indicating their preference for counseling modality. The
genetic counselor uses these patient preferences to set the genomic counseling session and to personalize result communication
and risk reduction recommendations. Tailored visual aids and result summary reports divide areas of risk (genetic variant, family
history, lifestyle) for each disease to facilitate discussion of multiple disease risks. Post-counseling, session summary reports are
actively routed to both the patient and their physician team to encourage review and follow-up. Given the breadth of genomic
information potentially resulting from genomic testing, this framework is put forth as a starting point to meet the need for scalable
genetic counseling services in the delivery of precision medicine.
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Introduction
Genetic counseling is a clinical service to help patients and
their families understand and apply genetic information, and
to assist in incorporating personalized strategies to help with
adjustment to and management of disease(s) and associated
risks (National Society of Genetic Counselors’ Definition
Task et al. 2006). When provided by genetic counselors,
genetic counseling also attends to the emotional ramifica-
tions of genetic information in a client-centered manner
(Smerecnik et al. 2009). A significant portion of a genetic
counseling session includes an informed pre-test consent
discussion (if genetic testing is to be undertaken), which
includes a discussion of potential testing options, possible
results, and discussion of the implications and potential
impact of results for the patient and family members.
Post-test disclosure typically focuses on application of test
results with in-depth discussion and education in the con-
text of personal and family history, psychosocial interven-
tion and support, and case management.
The Reciprocal Engagement Model (REM) of genetic
counseling practice best captures the patient-centered genetic
counseling process (National Society of Genetic Counselors’
Definition Task et al. 2006; Veach et al. 2007). The REM is
built on the tenets of patient-centered education and counsel-
ing, understanding and appreciation of the patient’s unique
situation, support and guidance to patients to build rapport
and trust, and facilitative decision-making. The REM incor-
porates the patient’s values, prior knowledge, beliefs, and ex-
periences, and allows for the development of a mutual rela-
tionship, which is at the core of the genetic counseling
process.
To achieve the goals of the REM in the context of genomic
service delivery, new “genomic counseling” strategies are
needed to address secondary findings identified in broad-
scale genomic testing, genomic screening (e.g., carrier test-
ing, population screening), elective genomic testing in
healthy individuals, and the combined effects of multiple
genetic variants and environmental factors as effectors of
disease risk (Hooker et al. 2014; Middleton et al. 2015;
Ormond 2013; Wicklund and Trepanier 2014). A more
comprehensive application of genomic results, which ex-
pands upon traditional genetic counseling approaches for
individual indicated conditions, has been termed genomic
counseling (Middleton et al. 2015; Mills and Haga 2014;
O'Daniel 2010; Ormond 2013; Shelton and Whitcomb
2015). Genomic counseling addresses many different types
of medical conditions, and may include a range of different
types of risks. Common diseases such as coronary heart
disease (CHD), stroke, Alzheimer’s disease, macular de-
generation, and non-Mendelian subtypes of cancer that
are typically addressed in genomic counseling differ from
monogenic Mendelian disease in that there are presumed
multiple low/moderate genetic variants, which alongside or
in combination with multiple non-genetic influences (e.g.,
smoking, other behaviors, and environmental influences),
confer increased risk (Khera et al. 2016; Skol et al. 2016).
Counseling strategies that address the multiple potential
conditions of interest that arise as a result of genome test-
ing may help individuals better understand their risk and
increase their likelihood of engaging in proactive health
behaviors. Furthermore, additional emphasis on health ed-
ucation and disease prevention in genomic counseling may
lead to a more motivational style of counseling (Mills and
Haga 2014; Ormond 2013).
Further integration of genetic and genomic counseling
services within the genomic results delivery process is
essential (Collins and Varmus 2015; Kaufman et al.
2012; Lewis et al. 2016). It is also timely given the rise
of large, population-wide efforts of genomic sequencing
to include the National Institutes of Health All of USSM
Research Program (Collins and Varmus 2015), the
100,000 Genomes Project in the UK, and other interna-
tional initiatives (Manolio et al. 2015) for which the re-
turn of individual genomic results is planned. While the
focus of clinical care and research has been on diagnostic
testing or screening for genomic variants with proven val-
ue and clinical utility, there is the expectation that pre-
symptomatic and elective genomic screening (e.g., per-
sonalized genetic health panels examining medically ac-
tionable genes such as the ACMG Secondary Findings
v2.0 (Kalia et al. 2017); polygenic risk scores for com-
mon disease; pharmacogenomics) and public health
screening programs will, at some point, extend to more
comprehensive genome sequencing technologies, in the
USA and abroad (Carey et al. 2016; Evans et al. 2013;
Facio et al. 2013; Linderman et al. 2016; Manolio et al.
2015). The ultimate goal of these initiatives is to provide
better predictions of risk for multiple diseases and medical
indications, medication safety/efficacy, and other informa-
tion (e.g., non-genetic risk influences) so that individuals
can take a more personalized and preventive approach to
health (Collins and Varmus 2015). Their success, and the
overall future scaling of genomic technologies into prima-
ry care and specialty settings, will require development of
novel, creative, and ultimately more effective counseling
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strategies. In the new era of genomic service delivery,
patient-centered practice must continue to promote the tenets
and goals of the REM (Redlinger-Grosse et al. 2017), while
capitalizing on the strengths of a limited genetic counseling
workforce (Force 2016).
We propose a framework (Fig. 1) of counseling compo-
nents and strategies that operationalizes the REM for the
scalable delivery of genomic results. Our framework is
based on theory, literature review, expert panel input, and
qualitative research (Sweet et al. 2016), with a specific
focus on application of these strategies to large-scale ge-
nomic sequencing. Our work seeks to apply existing REM
and genetic counseling best practices within the emerging
genomic counseling context.
Identification of Genomic Counseling Components
and Strategies
Our approach to identifying and developing genomic
counseling components and strategies, focused on the
disclosure of genomic results and subsequent follow up,
was developed using a multi-step iterative process. The
process included (1) formative qualitative research with
patients (those with chronic disease as well as healthy
participants) who had undergone elective genomic testing
and subsequently received multiple online potentially ac-
tionable results via the OSU-Coriell Personalized
Medicine Collaborative to assess their responses to and
preferences for counseling (Sweet et al. 2014); (2) exten-
sive literature review of genetic counseling service deliv-
ery models and health behavior theory; and (3) reflective
analysis (critical discussion) of the data in steps 1 and 2
with an expert panel of counselors with experience in
both Mendelian/single-gene genetic counseling and genomic
counseling. The formative research study (Sweet et al. 2016),
which informed the development of this framework, was
approved by Institutional Review Boards at the Ohio State
University Wexner Medical Center and the Coriell Institute
for Medical Research.
First, a grounded theory approach (Charmaz 2014) was
used to build the framework based on themes and patterns
that emerged from qualitative research (Sweet et al.
2016). The qualitative research was conducted with par-
ticipants in the OSU-Coriell Personalized Medicine
Collaborative (OSU-CPMC), who each received results
for up to 19 complex disease (e.g., age related macular
degeneration) and up to 7 drug response reports (e.g.,
CYP2C19 and Plavix) (Keller et al. 2010). Participants
received pre-test education and informed consent, and
completed online surveys that collected demographic,
medical and family history, lifestyle, and medication informa-
tion. This information, in concert with genetic results based on
genotyping for variants associated with common complex dis-
ease and drug response, was incorporated into personalized
online risk reports (Gharani et al. 2013; Stack et al. 2011). A
study web portal also offered text and multimedia format ed-
ucational materials to enable study participants to learn more
about basic genetic/genomic concepts, pharmacogenomics,
family history risk, relative risk and disease etiology, risk fac-
tors, and treatment and available preventative or risk-reducing
actions for each health condition and drug response reported.
OSU-CPMC study participants, who had received either in-
Fig. 1 Genomic counseling
framework: components and
strategies
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person or telephone genomic counseling, were notified of the
opportunity to participate in the qualitative interviews to in-
form development of this framework (Sweet et al. 2016).
Although the qualitative research was conducted with individ-
uals who had elected to undergo genomic screening, our sam-
ple included patients with chronic disease (hypertension, heart
failure) receiving in-person genomic counseling as part of a
randomized control trial (Sweet et al. 2016, 2017a, b) in an
academic medical setting.
Second, a transdisciplinary group of investigators from
across the country, including genetic counselors with ex-
pertise in cancer and cardiovascular genetics/genomics and
medical genetics/genomics, as well as investigators with
expertise in health communications and health behavior
research, worked together to analyze and further refine
data from the qualitative research and literature review
and group these components into goals and strategies to
develop our framework. This was done over the course of
several months via conference calls and offline work, and
multiple drafts of the genomic counseling framework were
circulated, reviewed, and iteratively revised until reaching
consensus (May–September 2015). The framework pre-
sented here, while based on qualitative research data, liter-
ature review, and expert opinion, is largely conceptual—in
essence, it is an approach to be refined and built-upon as
more empirical evidence is gathered on the effectiveness of
these strategies in practice.
Genomic Counseling Framework
The genomic counseling framework incorporates key aspects
of the REM and science-based best practices for genetic
counseling (National Society of Genetic Counselors’
Definition Task et al. 2006; Veach et al. 2007) and was
designed to accompany the receipt of multiple genomic
results in varied practice settings (Fig. 1). The counseling
approach remains patient-centered, and the counseling
agenda is patient-driven and action-oriented, with the
end-goal being the activation of patients toward healthy
behavior changes to reduce and manage their risk appro-
priately. Our framework incorporates counseling through
four components: (1) pre-test expectation setting and informed
consent for genomic testing, (2) automated contracting and
modality preference assessment, (3) tailoring of the session
based on patient pre-session preferences, and (4) enhancing
patient access and empowerment. In the following section, we
outline the conceptual and empirical basis for each component
(including links to the REM) and provide an overview of
activities in each component based on our current practice.
While designed for use in a genomic counseling setting where
multiple test results are provided, we also provide suggestions
for how components of this framework can be modified for
other patient care settings.
Component 1: Pre-Test Expectation Setting
and Consent
Strategy 1: Assessing and Setting Expectations
During Informed Consent
As illustrated in Fig. 1, the counseling process begins prior to
genomic testing focusing first on clear and open communica-
tion during the informed consent process. Effective genetic
counselor-patient communication is a key focus of the REM,
as the relationship is integral to genetic counseling (Veach
et al. 2007). We propose, as have others (Albada et al.
2012a; Jay et al. 2000), that patients must understand what
they can expect from any type of genetic/genomic test results
and follow up genomic counseling, prior to beginning the
process. Managing the expectations of patients prior to the
return of results also has been shown to increase genetic
counseling effectiveness and overall patient satisfaction with
the counseling process (Albada et al. 2012b; Cacioppo et al.
2016; Jay et al. 2000). Managing expectations (particularly in
terms of what genomic testing will not tell patients) is partic-
ularly important in genomic results counseling, given the
broad scope of results that may be available, representing both
rare and common complex disease. Patients may also have
unrealistic expectations about the predictive value and benefit
of genomic testing given the attention it has received in the
media and scientific worlds (Caulfield and Condit 2012).
Interpretation of these results also needs to take into account
the limitations of the technology used and the available data in
curated variant repositories (i.e., ClinVar). Furthermore, the
information a patient will receive from genomic testing will
depend on the indication (i.e., testing for a diagnostic indica-
tion versus pre-symptomatic elective testing in healthy pa-
tients); thus, defining and communicating expectations prior
to counseling factors prominently into the genomic counseling
framework.
The informed consent process should assess expectations
regarding the genomic information patients believe they are
going to receive, so that misconceptions can be addressed.
Furthermore, as suggested by others, less emphasis should
be placed on the standard elements of the consent process
and technological aspects of the testing (Bernhardt et al.
2015; Wynn 2016) and more on the counseling process itself.
This process of setting expectations aligns with the 2013
American College of Medical Genetics and Genomics policy
statement on informed consent for genomic sequencing
(Directors 2013). Indispensable information communicated
to the patient during informed consent should include (1) what
the patient will learn (and not learn) from receipt of genomic
information, including secondary and incidental findings; (2)
how much of their genetic data is included and what is being
analyzed; (3) how results might change over time; and (4) the
potential range and impact of results on their current and
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future healthcare (Bernhardt et al. 2015). In our experience,
providing familiar examples of genomic results for common
disease (e.g., coronary heart disease), while acknowledging
that results may not directly correlate with their own personal
medical or family history, is essential and helps to stimulate
patient questions.
The education component of the pre-test consent process
does not necessarily need to be done in-person or by phone,
nor by a clinical genetics expert. Past research suggests that
educational videos or interactive technologies may be a useful
means of communicating and assessing expectations prior to
informed consent, and reducing the amount of clinician time
necessary to provide this pre-test information while simulta-
neously shaping patient expectations (Shelton and Whitcomb
2015). Although a direct assessment of interactive tools in pre-
test decision-making has not been carried out for genome-
wide testing, a review of 15 different studies utilizing interac-
tive e-tools for pre-test decision-making (for more targeted
testing use scenarios) found that overall patient satisfaction
with consent was equivalent or better than in-person counsel-
ing and the knowledge aids appeared to minimize decisional
conflict (Birch 2015). In the studies that were used to develop
the genomic counseling framework, participants were en-
rolled in 1-h group sessions (e.g., 5–20 participants per group)
by a trained study recruiter who administered a PowerPoint
educational presentation (either by face-to-face or by use of a
video) that covered background information on DNA, genes,
and single nucleotide polymorphisms; the genetic basis of
common, complex disease; logistics including access to the
online web portal; composition of the online test reports; and
the availability of genomic counseling (Sweet et al. 2014). In
similar fashion, group pre-consent education and informed
consent is already performed in some hereditary disease
clinics (Albada et al. 2012a, b; Benusiglio et al. 2017),
and this approach could be expanded upon in many areas
of genetic counseling practice.
Strategy 2: Obtain Family History and Other Risk Factor
Information
Following informed consent and expectation setting,
obtaining and assessing medical and family history is an es-
sential next step for comprehensive assessment of disease risk
incorporating genomic information. We propose that much of
this process could be accomplished outside of the genetic
counseling session with the use of online family history tools
that assist with routine and systematic collection of family
history and standardize the assessment and referral process.
A few online family history assessment tools have been de-
veloped for this purpose, but much more work needs to be
done to explore the effects of online family history collection
on genetic counseling outcomes (Orlando et al. 2016;
Rubinstein et al. 2011). Prompting patients to use online
family history platforms, especially as more robust programs
to integrate and assess medical, family history, and lifestyle
information become available, may also help busy clinicians
(Guttmacher et al. 2004). As progress is made in standardizing
electronic health record (EHR) systems, updating of patient
medical and family history data via patient EHR portals will
continue to become more available, efficient, and reliable.
Further development of external patient portals and family
history intake by testing laboratories may also facilitate col-
lection of updated medical and family history data from pa-
tients. Alternatively, genetic counselor assistants could be uti-
lized to solicit pre-session family history and other lifestyle or
medical risk factor information by phone. This approach is
already being used in some genetic counseling practice set-
tings (Pirzadeh-Miller et al. 2016).
Although there are limits to the reliability of patient-
reported family history information, asking for this informa-
tion pre-session informs the interpretation of genomic se-
quence variation and gives the counselor a sense of the pa-
tient’s experience allowing for anticipatory guidance. In turn,
this could afford more time in the counseling session for the
counselor and patient to confirm family history information,
reach a shared understanding of the family dynamics and their
effects on the patient situation, and to discuss the “social his-
tory” aspects of this information (Redlinger-Grosse et al.
2017). In the OSU-CPMC study that inspired the develop-
ment of this framework, participants were administered online
surveys through a secure web portal that collected medical and
family history, as well as demographic, lifestyle, and medica-
tion information in order to produce personalized genomic
risk reports (Keller et al. 2010). The medical and family his-
tory information was explored in further detail in the in-person
genomic counseling sessions, to provide familial and cultural
context into the counseling relationship and for shared
decision-making (Sweet et al. 2017a, b), reflecting the tenets
of the REM.
Component 2: Assess Patient Preferences Using
Prompts
Strategy 1: Assess Patient Preferences for Result Return
and/or Discussion
Studies have shown that each individual is likely to have hun-
dreds of risk variants associated with both Mendelian and
complex phenotypes (McLaughlin et al. 2014; Tabor et al.
2014), and that most patients and health care professionals
prefer broad disclosure and ready access to these results
(Middleton et al. 2015; Yu et al. 2014). Woods et al. (2013),
in work assessing patient reactions to viewing laboratory test
results online, demonstrated high levels of patient satisfaction,
predominantly positive experiences, andmore patient empow-
erment. The ability to generate and provide genetic/genomic
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testing results and summaries online also shows great promise
(Buchanan et al. 2015; Schwartz et al. 2014; Tabor et al.
2017). Some individuals may prefer more easily accessible,
on-demand (e.g., online or mobile-based), and customizable
formats for genomic-based receipt of results and may have a
broader notion of what information may be meaningful or
actionable than genetic professionals (Gray et al. 2014;
Simmons et al. 2014). This work is in line with the recently
implemented 2014 US Health and Human Services mandate
that allows patients direct access to their lab results (Centers
for Medicare &Medicaid Services (CMS) 2014) and supports
the tenets of the REM.
Despite the growing availability of online report delivery,
not all patients will have reliable Internet access and some
patients may have privacy concerns and will prefer to receive
hard copy results. Nevertheless, genetic counselors can
still quickly assess patient preferences prior to testing to
include whether they want a phone call or another visit for
results disclosure, and when they want this to take place.
Regardless of delivery format, allowing patients to access
their results prior to genomic counseling gives them the
opportunity to evaluate their results, formulate questions,
and identify areas of interest or concern for discussion with
their genetic counselor to help facilitate more effective ge-
netic counselor-patient communication and to support pa-
tient autonomy. For the OSU-CPMC study, participants
could choose to view or not view each result, process re-
sults in their own time, and access self-directed education
and learning tools (Sweet et al. 2014).
Strategy 2: Assess Patient Preferences for Counseling
Modality
The genomic counseling framework assesses patient prefer-
ences for communication modality [telephone, telegenetic
(videoconferencing), or in-person] prior to counseling.
Based on our prior work (Sweet et al. 2016), and to help
increase efficiency and potential effectiveness of genomic
counseling, we developed an online survey (Supplementary
Fig. 1) for this purpose. This survey includes an assessment of
patient choice of communication mode and allows the coun-
selee to assist with refining the counseling agenda. This ap-
proach serves to establish a working contract, helps promote
autonomy, and clarifies patient concerns in line with the tenets
of the REM. Patients are more satisfied with counseling when
given the choice of how they want to discuss the results
(Baumanis et al. 2009; Sweet et al. 2016). Alternative service
delivery models to the in-person approach may include
counseling by phone or video (which can be supplemented
with materials routed or accessed by the participant via the
Internet or mobile devices) (Cohen et al. 2013; Meropol
et al. 2011). Although much of the alternative service delivery
work has been done in the cancer setting (Buchanan et al.
2016), this approach is expanding to other diseases (e.g.,
Alzheimer’s disease) (Christensen et al. 2017). These modes
of communication are well-accepted by patients, decrease the
amount of provider time (Cohen et al. 2016; Trepanier and
Allain 2014), and are effective in educating and supporting
patients, facilitating decision-making, and improving quality
of life outcomes as compared to in-person genetic counseling
(Schwartz et al. 2014). Utilization of technology beyond the
standard “in-person” mode of counseling may help facilitate
patient access to services that are limited due to geographical
or financial barriers, or when in-person counseling is not fea-
sible (Trepanier and Allain 2014). According to a November
2016 Pew Research Center survey, 88% of the general public
routinely access the Internet, 77% own a SmartPhone, and
70% utilize social media, suggesting alternative modes of
communication are becoming ever more readily accessible
(Smith 2016). Trade-offs may include the inability to fully
assess non-verbal behaviors/cues, the potential for dropped
or interrupted communication, and the need for additional
support for targeted patient populations (e.g., minority
women) (Peshkin et al. 2016).
Component 3: Tailoring the Genomic Counseling
Session
Strategy 1: Establishing a Counseling Agenda
Our previous work suggests that patients desire flexibility and
a personally tailored approach to their counseling (Sweet et al.
2016, 2017a, b). Therefore, a key piece of the genomic
counseling framework is assessment of participant areas of
concern, and points for discussion to help tailor the counseling
session. This information is obtained through the use of ques-
tion prompts (Supplementary Fig. 1) that can be submitted
online, emailed/texted, or mailed/captured by phone.
Strategies such as tailoring are proposed to influence key de-
terminants of health behavior change and are supported by
theories such as the Elaboration Likelihood Model (ELM)
(Petty and Cacioppo 1986). The ELM suggests that tailored
messages may be more effective because they are more rele-
vant to the individual and stimulate greater cognitive activity
or because elaboration on the message increases effectiveness
and the likelihood of behavior change (Kreuter and Wray
2003). Leveraging participant preferences and specific
questions about results also allows for more focused
contracting. In line with the REM (Veach et al. 2007), this
process also ensures that counselors know the patient’s
concerns. By directly addressing the most significant concerns
for a particular test result or disease risk upfront, the educa-
tional focus of the counseling session can be weighed toward
provision of evidence-based risk information (e.g., genetic
and environmental/lifestyle risk influences) associated with
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the development of the indicated disease in a manner that is
more personal and engaging to patients.
Strategy 2: Assess Risk Perceptions
Various health behavior models acknowledge that patient
comprehension and subsequent decision-making and action
on test results are affected by perceptions of disease risk
(e.g., Health Belief Model (Rosenstock 1990), Risk
Perception Attitude Framework (Rimal and Real 2003), and
Integrative Model of Health Behavioral Prediction (Fishbein
2008)). Risk perception can be influenced by a number of
factors, including personal experiences with disease, expecta-
tions of risk, as well as one’s emotional state (O'Neill et al.
2010). Our framework focuses on educating through explor-
ing the patient’s perceptions and concepts of risk to help un-
derstand the extent to which these align with more objective
risk estimates. Disease risk over- or underestimation can be
problematic if it is negatively associated with recommended
health behaviors and positive health outcomes (e.g., false re-
assurance from genomic results that inhibits engagement in
preventive health behaviors). When significant mismatches
between patient perceptions and objective risk estimates oc-
cur, counselors should attempt to further explore patient be-
liefs as well as offer additional insight on known risk factors.
Acknowledging the complexity of disease risk estimates si-
multaneously validates the patient’s existing viewpoint while
providing additional data to allow them to re-assess their per-
ceived risk. One approach is to identify and address causal
beliefs regarding perceived disease susceptibility, controllabil-
ity, and etiology (Austin 2015). A second approach is to in-
crease patient comprehension of risk and health actions that
might be taken to modify risk. The complexity of disease risk,
especially for common disease which often includes multiple
low/moderate and sometimes high-risk genetic variants in
combination with non-genetic influences, makes the educa-
tional aspects of genomic counseling more difficult than for
Mendelian single-gene disorders (Austin et al. 2014; Shelton
and Whitcomb 2015). Given that most individuals within the
general population already have trouble understanding genetic
risk information (McKibbin et al. 2014), and particularly
struggle with the multiple factors that contribute to risk
(DeFrank et al. 2013; Lautenbach et al. 2013), accessible pa-
tient education and preventive health strategies are a vital part
of the genomic counseling framework.
Strategy 3: Visual Aids
We propose two key strategies to help communicate geno-
mic risk. First, to help patients conceptualize multiple risk
factors and magnitudes of risk, we utilize visual aids.
Specifically, we used the analogy of pebbles splashing into
water (Fig. 2). The size of the pebble (representing a given
risk factor) varies depending on the magnitude of risk, and
as such, can be used to depict varying levels of risk. It
should be acknowledged that there are likely additional
ways to present magnitudes of risk and not to assume that
a single strategy works for everyone (Lautenbach et al.
2013). Research summarized by Garcia-Retamero et al.
has shown that using visual aids that have well-defined
elements, and that make use of part-to-whole relationships
(e.g., pictographs) may be more effective for vulnerable
populations or those with poor numeracy skills (Garcia-
Retamero and Cokely 2017). Theories of health communi-
cation suggest that the way that information is framed can
make the information more salient (noticeable and mean-
ingful) and influence how people evaluate and respond to
the information (Entman 1993; Tversky and Kahneman
1981). Counseling on the varied effect of genomic risk
variants, the limited predictive contribution of many of
these variants, and the polygenic and multifactorial nature
of common disease risk may foster a better understanding
of complex disease risk. Importantly, the counselor must
Fig. 2 Visual aid—rock images
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also attend to the patient’s subjective appraisal of their risk,
especially for more common and potentially modifiable
conditions, in order to help them understand the steps they
may be able to take to identify and engage in risk-reducing
health behaviors (Austin 2015).
A risk summary report (Fig. 3) summarizing results can be
used to teach patients about the varying contributions of mul-
tiple risk factors, and allows for the presentation of risk infor-
mation in multiple formats. Multiple risk reports from direct-
to-consumer labs could be condensed in similar fashion. The
risk summary report included an explicit breakdown of the
areas of risk (e.g., non-genetic versus genetic) for each disease
to facilitate discussion of the management of multiple types of
risk information. Although it is generally recommended that
absolute risk be communicated (Naik et al. 2012), the OSU-
CPMC study chose to report relative risks, which provided
context for disease risk, and allowed for the presentation of
risk based on multiple influences (genetic, family history, life-
style) using the same metric taken directly from published
literature. Use of absolute risk values in the OSU-CPMC
study would have required calculations based on lifetime risk
values that were not available for all diseases and reported
genotypes (Stack et al. 2011; Keller et al. 2010). For compar-
ison purpose, general population risks also were incorporated
into the summary report. Individual relative risk for each dis-
ease was described as being increased, decreased, or as “no
increase or decrease” in risk (i.e., average risk), with a separate
section to relay drug-response information in lay person lan-
guage. As some people prefer more detailed information, the
number of risk alleles and the genotype were also included.
The risk summary report can be made available online and/or
emailed or mailed to the patient prior to the session for use
during the genomic counseling session. This format also al-
lows for direct routing of the risk summary report into the
EHR for utilization by the patient’s healthcare team.
Strategy 4: Formulate Action Plan
The inclusion of effective health behavior recommendations,
reinforcements, or interventions (Austin 2015), perhaps with
use of evidence-based brief intervention strategies for promot-
ing positive health behavior changes (e.g., motivational
interviewing), may lead to adoption of health behaviors to
reduce risk (Mills and Haga 2014; Shelton and Whitcomb
2015). Focusing genomic counseling on the natural history
of a given disease, especially in light of modifiable lifestyle
changes, may help develop a personalized action plan (i.e., a
set of “next steps” collaboratively developed by the patient
and genetic counselor to help the patient manage their risks).
In the case of genomic counseling, patient actions may include
speaking with a health care provider about disease screening
methods (serum lipids; colonoscopy, etc.), making decisions
about potential treatments or actions to lower risk, meeting
with a health coach to set goals to achieve and maintain risk-
reducing health behavior changes, and sharing results with
other family members who may be at increased risk.
However, formulating successful action plans requires not on-
ly determining recommended action steps, but appraising the
patient’s attitudes and beliefs that may influence decision-
making (Welshimer and Earp 1989), where they are along
the continuum from pre-contemplation toward action
(Prochaska and Velicer 1997), and perceived or real barriers
(e.g., related to access of recommended services) they may
face in enacting behavioral change. The Integrative Model
of Behavioral Prediction (Fishbein 2008) suggests that factors
such as attitudes, perceived social norms for engagement in
certain behaviors (the expectations of others for our actions),
and efficacy (our confidence to act) are particularly important
to consider, as well as broader individual and social factors
such as culture and socioeconomic status (SES) that might
influence behaviors.
Component 4: Facilitate Patient Activation
Strategy 1: Use of Summary Documents
Summary letters after the genomic counseling process aid
patients in their personal understanding of information
and also in the dissemination of information to providers,
family members, and others who could be affected by
their genetic/genomic results. Format, content, and the
way in which this is delivered to the patient and the
healthcare team are all critical (Sweet et al. 2017a, b).
Although patients can often recall important information
provided to them in genetic counseling (Michie et al.
1997), summary letters serve as a longer-term reminder
of information shared during counseling. We recommend
an automated summary letter (Fig. 4) to supplement
patient-provider communications (Williams et al. 2016)
that is written in patient-friendly language, that outlines
test results and reinforces action steps, and that is easily
sharable with other providers and family members. This
summary letter should include a brief description of the test,
separating out results for multiple diseases (with personalized
risk factors); specific, personalized bulleted actions steps for
prevention and management; and when applicable, supportive
language to acknowledge patients already engaged in healthy
behaviors. An automated summary letter can be provided to
both the patient and provider team via the EHR (e.g., patient
portal) or sent to patients by mail.
Strategy 2: Working with Health Care Professionals
to Empower Patients
Health care professionals may not raise the topic of genomic
test results during consultations with patients, even when
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YOUR CORIELL DISEASE RISK SUMMARY
Paent Name
……………………………………………………………………………………………….………………………………..
This report is a summary of the nine Coriell Personalized Medicine Collaborave (CPMC) study results that you received through the CPMC web 
portal. These results provide informaon on your genec risk, your family history risk, and your environmental and lifestyle risk factors for eight 
diseases (listed below) and your genec result for one drug (Plavix®). Please note that CPMC assesses your risk based only on the factors 
presented in the report.  There may be other genec variants or other non-genec risk factors that also impact your risk.
Genetic Testing Results
Each person has two copies of every gene. Each copy may have small changes or variaons that can change your risk for a parcular disease. Some 
of these genec variants are associated with an increased risk of disease, while others are associated with a decreased risk of disease.
Family History Risk Results
Family history is one of the best predictors of disease risk, as it takes into account having similar genes and similar lifestyle and environmental 
exposures as your family members.  Risk based on family history was not evaluated for hemochromatosis.
Disease Variant Result Relave Risk Your Risk Evaluaon
General Populaon 
Lifeme Risk
Age-Related Macular Degeneraon TT 6.0 Increased 12%
Coronary Artery Disease CC 1.7 Increased 35.5%
Lupus GG 1 No increase or decrease 3%
Skin Melanoma CC 1 No increase or decrease 10%
Prostate Cancer CC 1 No increase or decrease 13%
Type 1 Diabetes (DM1) AG 0.3 * Decreased 2-3%
Type 2 Diabetes (DM2) GG 1 No increase or decrease 10%
Hemochromatosis GG 1 No increase or decrease <1%
Notes: For most diseases, a relave risk of 1 indicates you are at lower risk of developing the disease compared to someone with 1 or 2 copies of a risk 
variant; A relave risk above 1 indicates you are at a higher risk of developing the disease compared to someone with no copies of a risk variant. *For Type 
1 Diabetes: A relave risk of 1 indicates you are at a higher risk of developing the disease compared to someone with 1 or 2 copies of the protecve variant;
A relave risk below 1 means that you are at a lower risk to develop the disease compared to someone with no copies of the protecve variant.
Disease Relave Risk Your Risk Evaluaon
Age-Related Macular Degeneraon 1 No increase or decrease
Coronary Artery Disease 1.4 Increased
Lupus - No risk esmate available
Skin Melanoma 1 No increase or decrease
Prostate Cancer 1 No increase or decrease
Type 1 Diabetes (DM1) - No risk esmate available
Type 2 Diabetes (DM2) - No risk esmate available
Notes: A relave risk of 1 indicates you are at a lower risk of developing the disease compared to someone with a family 
history of the disease.  A relave risk above 1 indicates you are at a higher risk to develop the disease compared to someone 
with no family history of the disease.
Fig. 3 Risk summary report
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they are available in the EHR. This may be due to lack of
preparedness to discuss genomic results, or underestimating
the importance and/or clinical actionability of certain test re-
sults (Guttmacher et al. 2007; Vassy et al. 2013). Each of these
possible reasons for inaction can be addressed through active
alerting of the physician team regarding genomic consulta-
tions about potentially actionable results (Kho et al. 2013;
Shoenbill et al. 2014; Sweet et al. 2017a, b) and education
and decision support for patients with genomic results.
Optimizing the potential for clinical utility of genomic results
will also depend on a sustained multidisciplinary approach to
education and support for the non-geneticist physician
(Talwar et al. 2017; Vassy et al. 2015). Genetic counselors
and other health care providers (e.g., nurses, health coaches)
familiar with patient activation can also build patient confi-
dence and encourage patients to talk to their physicians about
their results.
Strategy 3: Data Sharing
Sharing genomic test results with relatives, especially when
a disease(s) has actionable components, allows opportunity
to identify other at-risk relatives, facilitate cascade testing
as appropriate, and may increase family-centered support
and communication. This may be particularly important if
test results include “Tier 1” findings (e.g., BRCA 1/2,
Lynch syndrome, familial hypercholesterolemia) where
cascade screening has shown significant benefits for family
members (Khoury et al. 2011). There are increasing oppor-
tunities to use social media platforms (e.g., Facebook) or
other platforms such as KinTalk to share results with rela-
tives (Lee et al. 2013; Ratzan 2011). A number of clinical
testing labs now provide open access and mobile platforms
that allow patients to share their genetic/genomic data.
These platforms remove many of the barriers to promote
Non-Genetic Risk Results
Non-genec risk factors such a smoking, diet, exercise or diagnosis with another health condion, also account for much of your disease risk. In 
fact, for some diseases much of your risk is due to non-genec risk factors. Based on the informaon you reported in the CPMC web portal, risk 
was evaluated for four diseases.  Risk based on lifestyle factors was not evaluated for Prostate Cancer, Type 1 Diabetes, or Hemochromatosis. 
Plavix® Drug Response Results
In the CPMC reports you were provided with informaon about how you might respond to certain drugs based on your genec make-up. The table 
below provides a summary of one medicaon, including the specific result. 
Disease Risk Factor Relave Risk Your Risk Evaluaon
Age-Related Macular Degeneraon Smoking 1.0 Increased
Coronary Artery Disease Smoking 1 No increase or decrease
Coronary Artery Disease Diabetes 1 No increase or decrease
Lupus Smoking 1 No increase or decrease
Type 2 Diabetes (DM2) BMI* 2.3 Increased
Notes: A relave risk of 1 means that you are at a lower risk of developing the disease compared to someone who has a given risk factor (smoking 
or increased BMI, for example). A relave risk above 1 means that you are at higher risk of developing the disease compared to someone without 
the risk factor.   *BMI = Body Mass Index (underweight, normal weight, overweight or obese)
Drug Result Notes
Plavix® (Clopidogrel) CYP2C19 *1/*17 -Ultra-Rapid Metabolizer
32% of People Receive this Result
Expected to process medicaon more quickly.  
Fig. 3 (continued)
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open data sharing, encourage research participation, allow
patients to become more engaged, and assist them in learn-
ing how other people manage similar health concerns
through self-advocacy (e.g., FORCE network for BRCA
mutation carriers). Easier sharing may also encourage other
family members to get tested or to act on results.
Fig. 4 Summary letter
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Discussion
To help increase the potential effectiveness of genetic counsel-
ing practice, as well as its efficiency, we propose a framework
of counseling components and strategies that operationalizes
the Reciprocal Engagement Model for the scalable delivery of
genomic results. The genomic counseling framework incor-
porates the collection of patient preferences (via online or
other tools) before, during, and after genomic testing to in-
crease efficiency of practice; incorporates key strategies to
help communicate and enhance patient understanding of com-
plex risk information; and defines a more integrative approach
to result delivery in the general medical care settings. We
advocate for the expansion of health education on preventa-
tive behavior and lifestyle changes in counseling to help fur-
ther support and accentuate the actual patient-centered
Fig. 4 (continued)
1122 Schmidlen et al.
Fig. 4 (continued)
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psychosocial counseling process. Our goal was to develop a
flexible, modifiable counseling approach that is able to be
used in emerging genomic counseling settings, as well as oth-
er clinical practice settings where a range of genetic test results
are returned simultaneously. The genomic counseling frame-
work is also imminently scalable and streamlined via the use
of web-based resources for the coming age of large-scale ge-
nomic testing and patient access to multiple results.
In this framework, we propose assessing and honor-
ing patient preferences for communication modality
(telephone, telegenetic, or in-person) prior to counseling
about the results. Utilization of delivery models beyond
the standard “in-person” mode of counseling will likely
help facilitate patient access to services that are limited
due to geographical or financial barriers, or when in-
person counseling is not feasible (Trepanier and Allain
2014), and these alternative service delivery models
have already been well-accepted by patients in some
disease areas (e.g., cancer) (Buchanan et al. 2015).
Furthermore, these alternate forms of communication in-
crease patient/client convenience, and expand the scope
of practice to include the ability to counsel multiple
family members simultaneously who are not all in the
same geographic location (Cohen et al. 2016; Trepanier
and Allain 2014).
Secondly, we propose that patient areas of concern, or
points of discussion for the counseling session, can be
assessed with the use of question prompts that could be made
available online, elicited by phone, emailed, mailed, or texted
to the patient. Having the counselee provide these preferences
pre-session could allow for even more pointed contracting and
targeted genetic counseling intervention than already typically
occurs. A patient not bringing up a particular area of concern
is also still helpful and presents opportunities for education
and information provision. This approach is especially rele-
vant when an individual is provided results for multiple dis-
ease risks, as provided by genomic testing. Tailored visual
aids and result summary reports divide areas of risk (genetic
variant, family history, lifestyle) for each disease, facilitating
viewing of multiple disease risks simultaneously. Post-
counseling summary reports can be actively routed to the pa-
tient and their physician team electronically to encourage re-
view and follow-up on recommended disease prevention/risk
reduction actions. Genetic counselors should continue to ex-
plore the utility of social media platforms and emerging mo-
bile health tools (Gallagher et al. 2016). This more participa-
tory approachmay be beneficial in helping patients who desire
to be more actively engaged in their health care, which, in
turn, can improve patient activation and produce positive
health outcomes.
Through our previous work, we have found that for in-
dividuals undergoing elective genomic testing, the degree
of genetic counseling intervention needed varies per patient
and per indication (Schmidlen et al. 2014; Sweet et al.
2016). Some individuals require specific genetic counsel-
ing for multiple risk reports or disease concerns, while
others may more intuitively understand that interpretation
of results for one condition is relevant to another. Although
our framework was developed to be patient driven, with the
primary focus on discussing the results the patient has most
interest in and for which there is increased risk, the inter-
personal relationship that is central to the genetic counsel-
ing process is also important here. For example, in
discussing how some variant results can impact medical
care (e.g., homozygous status for the AMD variant confers
a RR > 6.0) or to support decisions to make personal life-
style modifications to reduce disease risk, many patients
still require active counseling to help alleviate psychologi-
cal distress and promote a sense of autonomy and control.
We also found in our work that patients with chronic dis-
ease may have different motivations and represent more
varied socioeconomic status (SES) than “healthy” individ-
uals seeking predictive genomic risk information. These
groups of patients may also vary in their understanding
and response to multiple actionable genomic risk reports,
and may treat risk information related to their diagnosis
differently than risk information for other diseases.
Therefore, even as genetic counseling approaches become
more automated and online, there remains the need to ex-
plore personal and family dynamics. This can be achieved
in a manner similar to current genetic counseling practice:
by reviewing aspects of the personal and family history,
eliciting responses to concerns about disease risks that
may be present in the family, or by simply reflecting upon
the reason(s) an individual has elected to undergo testing in
the first place.
The genomic counseling framework is based on several
key health behavior theories, which provides a framework
for integrating concepts of agenda setting and multistep
workflow and allows for assessment of behavior constructs
such as perceived personal control, risk perception accura-
cy, and attitudes (Fishbein 2008). This framework also pro-
motes personal health behavior modification on three es-
sential socioecological levels (individual: receipt of poten-
tially actionable genomic results; interpersonal: interaction
with a genetic counselor; and organizational: interaction
with health care systems) (Division of Cancer Prevention
and Control 2015; Golden et al. 2015). The framework is
both theoretically and empirically based, taking into ac-
count messages and actions to be utilized in genomic
counseling to reduce risk and influence health behavior.
As such, we suggest that this framework could be further
developed and expanded upon to incorporate any type of
potentially actionable genomic test result, to include rare
Mendelian in addition to common multifactorial disease
as many of the essential elements of genetic counseling
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remain the same. It is notable that genetic counseling ap-
proaches for actionable Mendelian disease are in the midst
of rapid change given the expansion of (1) clinical molec-
ular testing to encompass multigene panels (Domchek et al.
2013), (2) the growing availability of online test report de-
livery, and (3) the increasing use of telephone/telegenetic
counseling services. Testing labs are also beginning to
make available panel-based approaches to medically ac-
tionable screening panels (based on the principles of the
ACMG 59 gene list) for healthy individuals. These panels
are not currently direct-to-consumer and typically incorpo-
rate genomic counseling, pre-test education, and informed
consent; for some, result delivery is available online.
Focused gene panels that capture actionable Mendelian dis-
eases are providing opportunities to meet growing consum-
er interest in actionable diseases, significantly impacting
current genetics practice, and highlighting the need for con-
tinued evolution of genomic counseling service delivery
and practice.
Given the breadth of genomic information likely to be in-
cluded in result reports as the use of genomic-based technol-
ogies continues to increase, further development of this frame-
work should help provide a scalable approach to the delivery
of precision medicine that capitalizes on evidence-based best
practices and incorporates patient preferences. To reach this
end goal, a number of hurdles must be overcome. Allowing
greater access to genomic counseling for multiple types of
results, as predicated by this framework, may make it more
difficult from a professional time management perspective.
Implementation of genomic testing/screening will ultimately
be driven by patient and healthcare provider demand, payers’
willingness to reimburse, and by assessing outcomes after
receiving genomic information and counseling. Genome-
wide testing will produce many findings, some of which are
medically actionable, and some which will have uncertain
clinical implications (e.g., VUSs, variants that are clinically
relevant but lack specific guidelines, variable penetrance, etc.)
with the potential to exacerbate some very difficult genetic
counseling issues related to uncertainty, patient engagement,
and decision-making (Bernhardt et al. 2015). Some of these
are addressed by this genomic counseling framework, others
might be approached through augmentations to genetic coun-
selor training, as well as more extensive training around the
psychology of uncertainty and evidence-based methods of
facilitated decision-making (Hooker et al. 2014). There are
appreciable startup costs associated with development of
web-based interfaces and counseling services. Significant
barriers also exist related to under-utilization of health ser-
vices by lower SES and selected racial/cultural subgroups
in the USA and abroad. Lastly, although many genetic/
genomic testing services now allow consumers to access
their results (and even genetic counselors) online, there
remains appreciable gaps by the general public in access
to, and use of, available technology and genetic counseling
services. Additional research on the expanding roles of
technology, genomic counseling service delivery outcomes,
and cost-effectiveness is warranted (Madlensky et al. 2017).
Conclusion
The genomic counseling framework was developed to meet
the challenges of providing genomic counseling for the
coming age of large-scale genomic testing and patient ac-
cess to multiple results. The components and strategies
elaborated in this framework serve the existing tenets of
the REM, encompass genetic counseling best practices,
and are grounded in empirical and theoretical research.
Furthermore, development of this framework was based
on formative research with patients receiving multiple dis-
ease and pharmacogenomics reports, and consultation with
experts in genetic and genomic counseling to provide broad
scope and applicability for any type of genomic result. The
components and strategies within this framework should
undergo further testing and subsequent refinement, with
studies currently underway. We believe that this genomic
counseling framework presents a first step toward
operationalizing the REM for a more scalable delivery of
patient-centered genomic counseling with the ultimate
goals of (1) reducing risk for both common and rare dis-
eases with genetic and genomic components in a proactive
approach and (2) helping patients and families adapt to and
cope with genetic health risks.
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